Clinical Trial Update: Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B [Phase 3]

View source ↗

Summary

This document reports a Phase 3 clinical trial evaluating a combination of PEG-Tα1 and Adefovir for HBeAg-positive chronic hepatitis B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Adefovir (adefovir)
• PEG-Tα1 (pegylated thymosin alpha-1)

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: Hepatitis B, Chronic | Phase 3 | Status: UNKNOWN